Two More Uses for Rituximab
The FDA has approved two additional uses for rituximab (Rituxan, Genen-tech/Biogen Idec) for patients with CD20-positive, B-cell non-Hodgkin’s lym-phoma (NHL): as a first-line treatment of previously untreated patients with fol-licular NHL in combination with cyclo-phosphamide, vincristine, and predni-solone (CVP) chemotherapy, and as a treatment for low-grade NHL in patients with stable disease or who have [...]
Read User's Comments